Hela Cell Infection
Hela Cell Infection - Related Videos
15:29
Microscopy-based Assays for High-throughput Screening of Host Factors Involved in Brucella Infection of Hela Cells
0 Views •
Cited by 6 •
2016
Two assays for microscopy-based high-throughput screening of host factors involved in Brucella infection are described. The entry assay detects host factors required for Brucella entry and the endpoint assay those required for intracellular replication. While applicable for alternative approaches, siRNA screening in HeLa cells is used to illustrate the protocols.
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
0 Views •
2025
We provide a step-by-step immunocytochemistry (ICC) methodology for detecting anti-MDA5. This approach involves cell fixation, permeabilization, antibody incubation, and imaging techniques, which allow for the accurate detection of anti-MDA5 autoantibodies, aiding in the diagnosis of rapidly progressing interstitial lung disease in myositis patients.
09:20
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
0 Views •
Cited by 6 •
2017
The present method serves to identify isoform-specific inhibitors of histone deacetylases (HDAC) in HeLa cells by the UHPLC-MS analysis of multiple substrates. This is an antibody-free method developed to reflect HDAC1 and HDAC6 activity in the living cell environment, in contrast to single-isoform cell-free assays.
09:03
HeLa Based Cell Free Expression Systems for Expression of Plasmodium Rhoptry Proteins
0 Views •
Cited by 16 •
2015
Expression of malarial proteins in cell based systems remains challenging. We demonstrate two step and one step IVT (in vitro translation) cell free expression systems for expressing malarial recombinant rhoptry proteins from HeLa cells. We use a Ni-resin affinity based purification system to purify the rhoptry proteins.
08:55
In vitro Transcription and Capping of Gaussia Luciferase mRNA Followed by HeLa Cell Transfection
0 Views •
Cited by 13 •
2012
This method describes high yield in vitro synthesis of both capped and uncapped mRNA from a linearized plasmid containing the Gaussia luciferase (GLuc) gene. The RNA is purified and a fraction of the uncapped RNA is enzymatically capped using the Vaccinia virus capping enzyme. In the final step, the mRNA is transfected into HeLa cells and cell culture supernatants are assayed for luciferase activity.
FAQs
Infection begins when a pathogen attaches to compatible receptors on the cell surface and enters the cell. Once inside, it uses host cellular machinery to support replication or growth. These linked events connect receptor availability, intracellular conditions, and pathogen activity to later observations such as altered gene expression, cytopathic effects, or cell death.
These variables establish the conditions under which infected and uninfected cells are compared. Pathogen dose represents the amount introduced, exposure time defines how long cells encounter it, and cell density describes the cellular environment during the experiment. Regulating them helps researchers interpret measured changes and compare results across experimental conditions.
They represent different measurable consequences of host-pathogen interaction. Cytopathic effects are visible changes in cell appearance, altered gene expression reflects changes in cellular activity, and cell death indicates loss of cellular viability. Examining these outcomes together can provide complementary evidence about how infection affects HeLa cells rather than relying on a single observation.
Microscopy can reveal changes in cell appearance, while immunostaining can identify infection-associated signals in cells. Molecular assays evaluate changes at the molecular level, including altered gene expression, and viability measurements indicate whether cells remain alive. Selecting one or several approaches allows researchers to connect visible, molecular, and functional outcomes.
Researchers expose HeLa cells to a virus or other intracellular pathogen while regulating pathogen dose, exposure time, and cell density. They then examine the cells using microscopy, immunostaining, molecular assays, or viability measurements. This sequence links experimental exposure to measurable infection-associated changes and supports systematic comparisons among conditions.
The model supports studies of virology and host-pathogen interactions, as well as antimicrobial and antiviral testing. It also contributes to vaccine research and analysis of cellular responses to infection. Because researchers can measure effects through imaging, molecular tests, or viability assessments, the system helps evaluate both pathogen-related changes and responses to experimental treatments.